Payment overview · 2025
General Payments
$409.11
22 reported records · 12 companies
Healthcare provider profile · identity verified
Hernando Moreno, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VALDOSTA, GA · NPI 1396950994
Verified facts
What the public records show
CMS Open Payments records show Hernando Moreno, MD received $409.11 in general payments during 2025 across 22 reported records.
Abbott Laboratories accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.97 | 19.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.84 | 17.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.90 | 12.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.49 | 8.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.73 | 7.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.98 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.99 | 6.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.08 | 5.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.84 | 4.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.20 | 4.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.55 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.54 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $409.11 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $80.97 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.90 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.49 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 587 | 134 |
| Losartan Potassium | Losartan Potassium | 587 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 93 |
| Lisinopril | Lisinopril | 293 | 79 |
| Metformin Hcl Er | Metformin Hcl | 291 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 71 |
| Simvastatin | Simvastatin | 264 | 72 |
| Omeprazole | Omeprazole | 255 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 59 |
| Potassium Chloride | Potassium Chloride | 233 | 54 |
| Metformin Hcl | Metformin Hcl | 229 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 64 |
| Meloxicam | Meloxicam | 178 | 49 |
| Glimepiride | Glimepiride | 168 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 41 |
| Gabapentin | Gabapentin | 163 | 49 |
| Sertraline Hcl | Sertraline Hcl | 148 | 34 |
| Alprazolam | Alprazolam | 147 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 33 |
| Famotidine | Famotidine | 120 | 35 |
| Furosemide | Furosemide | 120 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 32 |
| Montelukast Sodium | Montelukast Sodium | 102 | 27 |
| Eliquis | Apixaban | 100 | 24 |
| Trazodone Hcl | Trazodone Hcl | 98 | 20 |
| Trulicity | Dulaglutide | 94 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 41 |
| Alendronate Sodium | Alendronate Sodium | 78 | 19 |
| Lovastatin | Lovastatin | 77 | 19 |
| Ozempic | Semaglutide | 77 | 15 |
| Fenofibrate | Fenofibrate | 76 | 21 |
| Allopurinol | Allopurinol | 73 | 22 |
| Ezetimibe | Ezetimibe | 73 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Synthroid | Levothyroxine Sodium | 65 | 13 |
| Atenolol | Atenolol | 64 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 15 |
| Myrbetriq | Mirabegron | 62 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 14 |
| Carvedilol | Carvedilol | 59 | 18 |
| Ramipril | Ramipril | 59 | 13 |
| Januvia | Sitagliptin Phosphate | 58 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Glipizide Er | Glipizide | 52 | 14 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Valsartan | Valsartan | 39 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 11 |
| Celecoxib | Celecoxib | 35 | 14 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 19 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Glyburide | Glyburide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Mupirocin | Mupirocin | 23 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $409.11 · 22 records | Abbott Laboratories | ABRYSVO, Auvelity, COMIRNATY, FREESTYLE LIBRE, Flector, Fluad, Flucelvax, Leqembi, Licart, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TZIELD, Tirosint, WATCHMAN Access System, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error